- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05821049
A Study to Evaluate the Efficacy of UP165 on Sleep Quality and Mood State in Healthy Adults
A Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy of UP165 on Sleep Quality and Mood State in Healthy Adults
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Dr. Shalini Srivastava, MBBS, MD
- Phone Number: 02242172300
- Email: shalini.s@vediclifesciences.com
Study Contact Backup
- Name: Mr. Abhimanyu Kumar Sharma
- Phone Number: 02242172325
- Email: abhimanyu.s@vediclifesciences.com
Study Locations
-
-
Gujarat
-
Ahmedabad, Gujarat, India, 380006
- V.S. General Hospital
-
Vadodara, Gujarat, India, 390021
- Aman Hospital and Research Center
-
Contact:
- Dr. Mallika Aman Khanna, MBBS, MD (Medicine)
- Phone Number: 0265-2354594
- Email: mallsaman06@gmail.com
-
-
Maharashtra
-
Ahmedabad, Maharashtra, India, 380061
- Poojan Multispeciality Hospital
-
Dombivli, Maharashtra, India, 421201
- Shree Ashirwad Hospital
-
Contact:
- Dr. Kushal Bangar, M.B.B.S, DNB (Medicine)
- Phone Number: 9545664884
- Email: drkushal.bangar83@gmail.com
-
Ulhasnagar, Maharashtra, India, 421004
- Sai Cititcare
-
Contact:
- Dr. Prakash Kaurani, M.D. Physician
- Phone Number: 9766260204
- Email: tpa.saicriticare@gmail.com
-
-
Rajasthan
-
Jaipur, Rajasthan, India, 302039
- Maharaja Agrasen Superspeciality Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male and female subjects ≥20 and ≤ 60 years' old with moderate physical activity level as per International Physical Activity Questionnaire - Short Form(IPAQ - SF)
- Volunteers with body mass index between 18.5 and 29.9 kg/m2. Fairly bad or very bad subjective sleep quality with a score of 2 or 3 assessed as per PSQI Q9.
- Willing to maintain current dietary pattern, activity level, and stable bodyweight for the duration of the study, and refrain from any drastic lifestyle changes.
- Unable to fall asleep or unable to stay asleep (2 or more waking episodes during sleep at least twice a week but not more than four times)
- Agrees to maintain current sleep schedule throughout the study
- Agrees to stay in the current time zone for the duration of the study
- Subjects ready to give voluntary, written, informed consent to participate in the study.
- Willing to complete all study procedures including study-related questionnaires and comply with study requirements.
Exclusion Criteria:
- Subjects diagnosed with sleep disorders secondary to another health problem.
- Consumption of hypnotic drugs (<3 months before inclusion).
- Subjects with a history of caffeine consumption post 6:00 pm.
- Individuals taking any other sleep supplements and are unwilling to stop taking those supplements for the duration of the study period
- Recent history of physical, emotional, social trauma within last three months.
- Participants who are not medication (which are likely to impact sleep quality or pattern) free for at least 4 weeks apart from contraceptive pills
- Subjects who consume pain-relieving medications more than once per week.
- Individuals who have night terrors regularly
- Individuals who regularly sleepwalk
- Individuals who work at night shifts.
- Individuals who have regular bad dreams
- Use of the following medications during the study period: oral or injectable corticosteroid, sedating antihistamines (e.g. cold, allergy, motion sickness), psychotropic medications or hypnotics, benzodiazepine, narcotics, any illicit drugs
- Gastro-intestinal, hepatic, respiratory, psychiatric, kidney, or cardiovascular disorder (<3 months before inclusion),
- Recent (<3 months before inclusion) change in lifestyle (food, body weight, sport, drug, and/or dietary supplement),
- Students having regular class and assignments
Subjects addicted to digital media who exhibit at least five of the following symptoms currently:
i) Preoccupation with the digital media use j) Withdrawal symptoms that occur when digital media use is not possible k) Build-up of a tolerance that requires increasing amounts of digital media use to satisfy cravings l) Unsuccessful attempts to stop or limit digital media use m) Replacement of previously pleasurable activities with digital media use n) Unwillingness to stop digital media use despite its negative consequences o) Being deceptive about digital media use p) Using digital media use as a coping mechanism
- Addiction or history of substance abuse,
- Consumption of more than 3 glasses of alcohol per day,
- Pregnant or lactating woman,
- Lifestyle habits which would modify the wake-sleep rhythm, or which was expected to be modified during the study period (e.g., night work), and finally,
- Known allergy to the IP.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: UPI65 (Low Dose)
One capsule to be taken 60 ± 10 mins before bed
|
Red colored Capsules
|
Active Comparator: UPI65 (High Dose)
One capsule to be taken 60 ± 10 mins before bed
|
Red colored Capsules
|
Placebo Comparator: Placebo
One capsule to be taken 60 ± 10 mins before bed
|
Red colored Capsules
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To assess the efficacy of the Investigational Product (IP) from baseline on
Time Frame: throughout the study period (approximately 28 days)
|
Sleep statistics (sleep quality thoughout the study) by using the watch known as Garmin vivosmart 4 Tracker.
This watch will be used to measure the deep sleep, REM sleep and wake-up time in hours.
|
throughout the study period (approximately 28 days)
|
To assess the efficacy of the Investigational Product (IP) from baseline on
Time Frame: Day 28
|
The change in sleep index through the global scores of the Pittsburgh Sleep Quality Index (PSQI)
|
Day 28
|
To assess the efficacy of the Investigational Product (IP) from baseline on
Time Frame: Day 21
|
The change in sleep index through the global scores of the Pittsburgh Sleep Quality Index (PSQI)
|
Day 21
|
To assess the efficacy of the Investigational Product (IP) from baseline on
Time Frame: Day 14
|
The change in sleep index through the global scores of the Pittsburgh Sleep Quality Index (PSQI)
|
Day 14
|
To assess the efficacy of the Investigational Product (IP) from baseline on
Time Frame: Day 7
|
The change in sleep index through the global scores of the Pittsburgh Sleep Quality Index (PSQI)
|
Day 7
|
To assess the efficacy of the Investigational Product (IP) from baseline on
Time Frame: Day 28
|
Mood using POMS-A (Profile of Moods States - Abbreviated version)
|
Day 28
|
To assess the efficacy of the Investigational Product (IP) from baseline on
Time Frame: Day 21
|
Mood using POMS-A (Profile of Moods States - Abbreviated version)
|
Day 21
|
To assess the efficacy of the Investigational Product (IP) from baseline on
Time Frame: Day 14
|
Mood using POMS-A (Profile of Moods States - Abbreviated version)
|
Day 14
|
To assess the efficacy of the Investigational Product (IP) from baseline on
Time Frame: Day 7
|
Mood using POMS-A (Profile of Moods States - Abbreviated version)
|
Day 7
|
To assess the efficacy of the Investigational Product (IP) from baseline on
Time Frame: Day 28
|
Salivary cortisol levels immediately after waking up in the morning (before doing any activity)
|
Day 28
|
To assess the efficacy of the Investigational Product (IP) from baseline on
Time Frame: Day 21
|
Salivary cortisol levels immediately after waking up in the morning (before doing any activity)
|
Day 21
|
To assess the efficacy of the Investigational Product (IP) from baseline on
Time Frame: Day 14
|
Salivary cortisol levels immediately after waking up in the morning (before doing any activity)
|
Day 14
|
To assess the efficacy of the Investigational Product (IP) from baseline on
Time Frame: Day 7
|
Salivary cortisol levels immediately after waking up in the morning (before doing any activity)
|
Day 7
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- UI/220902/UP/SQMS
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sleep Disturbance
-
Università degli Studi di BresciaCompletedSleep Phase Rhythm DisturbanceItaly
-
University of BergenGlamoxCompletedSleep | Sleep Deprivation | Shift-Work Related Sleep DisturbanceNorway
-
Sam Houston State UniversityThe University of Texas Health Science Center, Houston; Memorial Hermann Texas...CompletedSleep Disturbance in Hospitalized Antepartum PatientsUnited States
-
The First Affiliated Hospital of Xiamen UniversityNot yet recruitingPostoperative Sleep Disturbance
-
Pacific UniversityCompletedInsomnia | Shift-Work Related Sleep DisturbanceUnited States
-
Erasmus Medical CenterNational Institute for Public Health and the Environment (RIVM); Netherlands...RecruitingShift-Work Related Sleep DisturbanceNetherlands
-
University of California, San FranciscoRecruiting
-
Riphah International UniversityCompletedSleep Disturbance in AthletesPakistan
-
University of ArizonaWalter Reed Army Institute of Research (WRAIR)CompletedSleep Deprivation | Caffeine | Shift-Work Related Sleep DisturbanceUnited States
-
Fred Hutchinson Cancer CenterNational Institute on Aging (NIA)CompletedHot Flashes | Sleep | Menopause | Vasomotor DisturbanceUnited States
Clinical Trials on UPI65 (Low Dose)
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingRecurrent Mantle Cell Lymphoma | Refractory Mantle Cell LymphomaUnited States
-
Emory UniversityNational Cancer Institute (NCI)TerminatedPneumonia | Coronavirus Infection in 2019 (COVID-19) | Severe Acute Respiratory Syndrome (SARS) PneumoniaUnited States
-
Beijing Northland Biotech. Co., Ltd.CompletedSafety and Efficacy Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction.InfarctionAcute Myocardial InfarctionChina
-
MedImmune LLCCompletedNon-alcoholic Fatty Liver Disease (NAFLD) | Non-alcoholic Steatohepatitis (NASH)United States, Puerto Rico
-
Lucozade Ribena SuntoryKing's College LondonCompletedPostprandial PeriodUnited Kingdom
-
Postgraduate Institute of Medical Education and...Completed
-
Indonesia UniversityMedika Natura Sdn BhdCompleted
-
Yiling Pharmaceutical Inc.CompletedPharmacokinetics | Healthy Adult Subjects | Safety and TolerabilityUnited States
-
CalciMedica, Inc.CompletedSystemic Inflammatory Response Syndrome | Acute PancreatitisUnited States
-
VA Office of Research and DevelopmentTerminatedAtherosclerosis | Anemia | CKD | CardiovascularUnited States